Jose A Rey

1.1k total citations
38 papers, 848 citations indexed

About

Jose A Rey is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, Jose A Rey has authored 38 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 11 papers in Pharmacology and 5 papers in Cognitive Neuroscience. Recurrent topics in Jose A Rey's work include Schizophrenia research and treatment (12 papers), Bipolar Disorder and Treatment (7 papers) and Pharmacology and Obesity Treatment (5 papers). Jose A Rey is often cited by papers focused on Schizophrenia research and treatment (12 papers), Bipolar Disorder and Treatment (7 papers) and Pharmacology and Obesity Treatment (5 papers). Jose A Rey collaborates with scholars based in United States and Saudi Arabia. Jose A Rey's co-authors include Clayton English, Camille Tessitore King, Benjamin Chavez, Jessica Greenwood, Lauren S. Schlesselman, Rafael A. Rivas-Vazquez, Raymond L. Ownby, William C. Mobley, Kevin A. Clauson and Joshua Caballero and has published in prestigious journals such as Psychopharmacology, European Journal of Pharmacology and Annals of Pharmacotherapy.

In The Last Decade

Jose A Rey

34 papers receiving 808 citations

Peers

Jose A Rey

PHARM

PMH

EDM

PHYSI

CMN

Daria Piacentino Italy

Barbara R. Haight United States

James F. Pradko United States

Susan M. Learned United States

Padideh Ghaeli Iran

Ralf Uebelhack Germany

Randall J. Mack United States

Carol B. Rockett United States

Amber N. Edinoff United States

Christina Dording United States

Daria Piacentino Italy

Jose A Rey

393 ×1.0

PHARM

289 ×1.6

PMH

161 ×1.0

EDM

143 ×1.0

PHYSI

104 ×0.8

CMN

Citations per year, relative to Jose A Rey Jose A Rey (= 1×) peers Daria Piacentino

Countries citing papers authored by Jose A Rey

Since Specialization

Citations

This map shows the geographic impact of Jose A Rey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jose A Rey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jose A Rey more than expected).

Fields of papers citing papers by Jose A Rey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jose A Rey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jose A Rey. The network helps show where Jose A Rey may publish in the future.

Co-authorship network of co-authors of Jose A Rey

This figure shows the co-authorship network connecting the top 25 collaborators of Jose A Rey. A scholar is included among the top collaborators of Jose A Rey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jose A Rey. Jose A Rey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pham, Huy P., et al.. (2024). Antibiotic-induced neuropsychiatric toxicity: epidemiology, mechanisms and management strategies –a narrative literature review. Drugs in Context. 13. 1–18. 7 indexed citations

Matthews, Thomas J., et al.. (2024). Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review. Psychopharmacology. 241(11). 2191–2203.

Levy, Arkene, et al.. (2022). Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model. Molecular Biology Reports. 50(2). 1765–1784. 5 indexed citations

Nguyen, Quan Dong, et al.. (2022). Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder. Journal of Pharmacy Technology. 38(5). 304–313. 2 indexed citations

Greenwood, Jessica, et al.. (2020). Lumateperone: A Novel Antipsychotic for Schizophrenia. Annals of Pharmacotherapy. 55(1). 98–104. 34 indexed citations

Greenwood, Jessica, et al.. (2020). Opicapone: A third generation COMT inhibitor. Clinical Parkinsonism & Related Disorders. 4. 100083–100083. 12 indexed citations

Rey, Jose A, et al.. (2019). <p>Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice</p>. Neuropsychiatric Disease and Treatment. Volume 15. 449–456. 7 indexed citations

Rey, Jose A, et al.. (2019). Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.. PubMed Central. 44(6). 340–375. 85 indexed citations

Rey, Jose A, et al.. (2019). Perseris^TM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.. PubMed. 44(8). 460–466. 7 indexed citations

10.

Caballero, Joshua, Raymond L. Ownby, Jose A Rey, & Kevin A. Clauson. (2015). Cognitive and Performance Enhancing Medication Use to Improve Performance in Poker. Journal of Gambling Studies. 32(3). 835–845. 6 indexed citations

11.

King, Camille Tessitore, et al.. (2013). Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.. PubMed. 38(9). 525–34. 48 indexed citations

12.

English, Clayton, et al.. (2010). Milnacipran (Savella), a Treatment Option for Fibromyalgia. Europe PMC (PubMed Central). 35(5). 261–266. 6 indexed citations

13.

Rey, Jose A, et al.. (2009). Iloperidone (Fanapt): An FDA-Approved Treatment Option for Schizophrenia. PubMed Central. 34(11). 606–613. 7 indexed citations

14.

Rey, Jose A, et al.. (2008). Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.. PubMed. 33(12). 690–4. 51 indexed citations

15.

Chavez, Benjamin, et al.. (2007). Atypical Antipsychotics in Children with Pervasive Developmental Disorders. Pediatric Drugs. 9(4). 249–266. 20 indexed citations

16.

Rey, Jose A, et al.. (2006). Pharmacological Agents for the Treatment of Adult Attention Deficit Hyperactivity Disorder: A Review of the Literature. Journal of Pharmacy Practice. 19(6). 336–341. 1 indexed citations

17.

Ward, Ceressa T., et al.. (2003). Establishing a Distance Learning Site for a Traditional Doctor of Pharmacy Program. American Journal of Pharmaceutical Education. 67(1). 20–20.

18.

Ward, Ceressa T., et al.. (2003). Establishing a Distance Learning Site for a Traditional Doctor of Pharmacy Program. American Journal of Pharmaceutical Education. 67(1). 20–20. 6 indexed citations

19.

Rey, Jose A, et al.. (2002). The discovery and status of sibutramine as an anti-obesity drug. European Journal of Pharmacology. 440(2-3). 119–128. 98 indexed citations

20.

Rey, Jose A, et al.. (1993). Pharmaceutical Services at a Medical Site After Hurricane Andrew. American Journal of Health-System Pharmacy. 50(9). 1896–1898. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact